Pharma News, 2024

Reeves’ 2024 budget promises life sciences investment

AbbVie's Skyrizi snatches sales crown from Humira as company lifts full-year profit guidance

GSK axes vaccine from $2.1B deal, switching to preclinical successor over 'increased competition'

The European Commission (EC) has approved AstraZeneca‘s Fasenra (benralizumab) as an add-on therapy for adults with relapsing or refractory eosinophilic granulomatosis with polyangii...

Genprex, Inc., a clinical-stage gene therapy company, announced positive preclinical results for its lead drug candidate, Reqorsa® (quratusugene ozeplasmid) Gene Therapy, at the recent EORTC-...

Astellas Pharma has announced the withdrawal of its marketing authorisation application for IZERVAY (avacincaptad pegol, ACP) intravitreal solution to treat geographic atrophy (GA) sec...

Digital Science, a technology company serving stakeholders across the research ecosystem, is today calling for greater awareness of the impact that a myriad of fast-developing technologies are having ...

Social media has become an excellent tool for targeting specific patients for clinical trials, says Chris Adams, the CEO at Andarix Pharmaceuticals, a biotech developing targeted oncology therapies.

At the Outsourcing in Clinical Trials Conference, key opinion leaders shared predictions for workflow changes due to AI.

Novo Nordisk just released data from a clinical trial featuring its oral semaglutide treatment, Rybelsus. Rybelsus is an oral glucagon-like peptide-1 (GLP-1) agonist and sibling medication to ...

With new readouts, Johnson & Johnson's Tremfya and Eli Lilly's Ebglyss are further proving their worth in separate immunology areas. Key drugs from Johnson & Johnson and Eli Lilly stand to...

Previous studies suggest that taurine (2-aminoethanesulfonic acid) supplementation may attenuate atherosclerosis by reducing lipid levels. However, energy drinks containing taurine have been s...